Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Abeona Therapeutics (ABEO) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Abeona Therapeutics (ABEO) over the last 13 years, with Q2 2025 value amounting to 5698.0%.

  • Abeona Therapeutics' EBIT Margin changed N/A to 5698.0% in Q2 2025 from the same period last year, while for Sep 2025 it was 20802.25%, marking a year-over-year change of. This contributed to the annual value of 1346.71% for FY2023, which is 22540600.0% up from last year.
  • As of Q2 2025, Abeona Therapeutics' EBIT Margin stood at 5698.0%.
  • Abeona Therapeutics' EBIT Margin's 5-year high stood at 97191.67% during Q4 2021, with a 5-year trough of 19023.53% in Q4 2022.
  • For the 4-year period, Abeona Therapeutics' EBIT Margin averaged around 7728.77%, with its median value being 301.54% (2023).
  • Its EBIT Margin has fluctuated over the past 5 years, first surged by 976743300bps in 2021, then crashed by -1162152000bps in 2022.
  • Quarter analysis of 4 years shows Abeona Therapeutics' EBIT Margin stood at 97191.67% in 2021, then plummeted by -120bps to 19023.53% in 2022, then skyrocketed by 98bps to 301.54% in 2023, then crashed by -1790bps to 5698.0% in 2025.
  • Its EBIT Margin stands at 5698.0% for Q2 2025, versus 301.54% for Q2 2023 and 19023.53% for Q4 2022.